Crossref
74151 Characterizing immune checkpoint inhibitor-associated vitiligo: a single-institution cohort
Journal of the American Academy of Dermatology · 2026-07 · 95 (1) · AB98
DOI: 10.1016/j.jaad.2026.04.402 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Academy of Dermatology, 2026-07. Verfasst von Katie Lu und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Lu, K., Enriquez, K., & Dobry, A. (2026). 74151 Characterizing immune checkpoint inhibitor-associated vitiligo: a single-institution cohort. Journal of the American Academy of Dermatology, 95(1), AB98. https://doi.org/10.1016/j.jaad.2026.04.402
Vancouver
Lu K, Enriquez K, Dobry A. 74151 Characterizing immune checkpoint inhibitor-associated vitiligo: a single-institution cohort. Journal of the American Academy of Dermatology. 2026;95(1):AB98. doi:10.1016/j.jaad.2026.04.402
BibTeX
@article{Lu2026,
author = {Lu, Katie and Enriquez, Kristen and Dobry, Allison},
title = {74151 Characterizing immune checkpoint inhibitor-associated vitiligo: a single-institution cohort},
journal = {Journal of the American Academy of Dermatology},
year = {2026},
volume = {95},
number = {1},
pages = {AB98},
doi = {10.1016/j.jaad.2026.04.402}
}
EUVIMED